Updates are available Correction dated 2019-01-07

Article History

Received: 4 December 2017

Revised: 12 June 2018

Accepted: 6 September 2018

First Online: 3 October 2018

Change Date: 7 January 2019

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41380-018-0311-2

Compliance with ethical standards

:

: LCC, MF, BBH, and HJ declare that they have no conflict of interest. CD: Dr. DeBattista has received grant support from Janssen, Neuronetics, St. Jude, and Biolite. He has served on the Advisory Board of Alkermes. CC: Dr. Cusin receives funding from NIMH (R01MH102279) and has received consulting fees from Janssen Pharmaceuticals, Takeda, Boehringer, Lundbeck. She has also participated in research funded by Janssen, Medtronic, Otsuka, Takeda. MF: reports 3-year disclosures as below: all lifetime disclosures can be viewed online at: ; research support: Alkermes, Inc., Johnson & Johnson, Axsome, Acadia Pharmaceuticals, Cerecor, Lundbeck Inc., Neuralstem, Otsuka, Taisho, Marinus Pharmaceuticals, BioHaven, Takeda, Vistagen, Relmada Therapeutics Inc., Stanley Medical Research Institute (SMRI), National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH), and PCORI. Dr. Fava has not done any personal consulting. Any consulting he has done has been on behalf of Massachusetts General Hospital. Stock/Other Financial Options: Equity Holdings: Compellis; PsyBrain, Inc. Royalty/patent, other income: patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven. Patents for pharmacogenomics of Depression Treatment with Folate (US_9546401, US_9540691). Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte. Ltd. MPF: over the past 3 years, Dr. Freeman has received research support from: Takeda, JayMac, and Sage; she has served in advisory boards of: Janssen, Sage, JDS therapeutics, Sunovion, and Takeda; she has served in the Independent Data Safety and Monitoring Committee of Janssen (Johnson&Johnson); she has served as a medical editor for the GOED newsletter. Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry [Current Registry Sponsors: Teva, Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Forest/Actavis (2016-Present), Sunovion Pharmaceuticals, Inc. (2011-Present)]. As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. DFI: Dr. Ionescu is an employee of Janssen Pharmaceuticals and, within the past year, has received grant funding with salary support from the Brain and Behavior Research Foundation and the NIMH for ketamine research. DVI: In the past 3 years, Dr. Iosifescu has received consultation fees from Alkermes, Axsome, MyndAnalytics (CNS Response), Jazz, Lundbeck, Otsuka, Sunovion, and has received research support (through his academic institutions) from Alkermes, Astra Zeneca, Brainsway, LiteCure, Neosync, Roche, Shire. MJ: Dr. Jha has obtained contracted research support from Acadia Pharmaceuticals and Janssen Research & Development. SJM: over the past 3 years, Dr. Mathew has received consulting fees from Acadia, Alkermes, Allergan, Bracket, Cerecor, Fortress Biotech, Otsuka, and Valeant; he has received research support from: Janssen and NeuroRx; he has also received support from facilities and resources of the Michael E. Debakey VA Medical Center and the Johnson Chair for Research from Baylor College of Medicine. JM: in the past 3 years, Dr. Murrough has provided consultation services to Allergan, Fortress Biotech, Novartis, Janssen Research and Development, Genentech, and ProPhase, and has received research support from Avanir Pharmaceuticals. Dr. Murrough is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders as well as on patents pending for lithium to extend the antidepressant effect of ketamine and ketamine plus lithium as a treatment for suicidal ideation. The Icahn School of Medicine (employer of Dr. Murrough) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine if it is approved for the treatment of depression. Dr. Murrough is not named on this patent and will not receive any payments. GIP: over the past 3 years, Dr. Papakostas has consulted to: Lundbeck, Sunovion, Brainsway, Pfizer, Boston Pharmaceuticals*, Novartis*, Acadia*, Axsome*, Genomind*, and Mylan* (*on behalf of Massachusetts General Hospital). He has received honoraria from: Lundbeck, Grunbiotics-Mylan, Takeda, Alkermes, Pfizer, Pharma Trade SAS, Asofarma, Sunovion, Brainsway, and Unilab Philippines. He has received research support from Neuralstem Inc and Tal Medical. GS: Dr. Sanacora has received consulting fees form Allergan, Alkermes, AstraZeneca, Biohaven Pharmaceuticals, Genentech, Janssen, Lundbeck, Merck, Navitor pharmaceuticals, Noven pharmaceuticals, Sage Pharmaceuticals, Takeda, Taisho Pharmaceuticals, Teva Pharmaceuticals and Vistagen Therapeutics over the last 36 months. He has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Johnson & Johnson, Hoffman La-Roche, Merck & Co., Naurex and Servier over the last 36 months. Free medication was provided to Dr. Sanacora for an NIH-sponsored study by Sanofi-Aventis. In addition, he holds shares in Biohaven Pharmaceuticals and is a co-inventor on a patent “Glutamate agents in the treatment of mental disorders” Patent number: 8778979. AFS: Dr. Schatzberg has served as a consultant for Alkermes, Avanir, Bracket, Lundbeck/Takeda, McKinsey, Myriad Genetics, Neuronetics, and Owl and as a speaker for Merck and Pfizer; he holds equity in Corcept (co-founder), Gilead, Incyte, Intersect ENT, Merck, Owl, Seattle Genetics, Titan, and Xhale; he has research funding from Janssen; and he is listed as an inventor on pharmacogenetic and mifepristone patents from Stanford University. MHT: Consulting/Advisory Board: Alkeremes Inc., Akili Interactive, Allergan Pharmaceuticals, Arcadia Pharmaceuticals, Avanir Pharmaceuticals, Brintellix Global, Bristol Myers Squibb, Caudex, Cerecor, Forest Pharmaceuticals, Global Medical Education Inc, Health Research Associates, Insys, Johnson & Johnson Pharmaceutical Research & Development, Lilly Research Laboratories, Lundbeck Research USA, Medscape, Merck & Co. Inc, Mitsubishi Pharma, MSI Methylation Sciences–Pamlab Inc., Navitor, Otsuka America Pharmaceutical Inc., One Carbon Therapeutics, Otsuka America Pharmaceutical Inc., Pfizer Inc, Takeda Global Research. Royalties: Janssen Research and Development LLC. Author Agreement: Janssen Asia Pacific, Oxford University Press. Honoraria: American Psychiatric Association. Grants: Agency for Healthcare Research and Quality (AHRQ), Cancer Prevention and Research Institute of Texas (CPRIT), National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Advancing Translational Sciences (NCATS), Johnson & Johnson, PCORI. STW: Dr. Wilkinson acknowledges support from the Agency for Healthcare Research and Quality (AHRQ; K12HS023000), the NIMH (T32MH062994), the Brain and Behavior Research Foundation (formerly NARSAD), the Robert E. Leet and Clara Guthrie Patterson Trust, the American Foundation for Suicide Prevention and the Yale Department of Psychiatry. Dr. Wilkinson has received consulting fees from Janssen Research & Development and from Guidepoint.